Periodic Reporting for period 1 - PeptiCHIP (PEPTICHIP: Streamlined identification of tumour neoantigens for personalised anti-cancer immunotherapy)

Identification of HLA class I ligands from the tumour surface is essential for designing T-cell mediated anti-cancer therapies. However, the immunopurification process for isolating MHC-I-restricted tumour-specific peptides has been the major limiting factor for reliable...